About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, November 21st, 2017

The QualityStocks
Daily Stock List


BioLargo, Inc. (BLGO)

Tiny Gems, FeedBlitz, Equities.com, Stock News Now, Promotion Stock Secrets, SECFilings, TopPennyStockMovers, SmallCapVoice, and Penny Sleuth reported previously on BioLargo, Inc. (BLGO), and we report on the Company today, here at the QualityStocks Daily Newsletter.

A sustainable science and technology company, BioLargo, Inc. delivers practical solutions for clean water, clean air, and advanced wound care. The Company delivers technology-based products that help solve some of the globe’s most important problems that threaten water, food, agriculture, healthcare and energy. BioLargo is headquartered in Westminster, California.

The Company’s subsidiary is BioLargo Water, Inc. BioLargo Water showcases the Advanced Oxidation Systems, including its AOS Filter. This is a product in development specifically designed to eliminate common, troublesome, and toxic contaminants in water in a fraction of the time and expense of present technologies.

The BioLargo® AOS Filter is the Company’s featured AOS Filter system. The BioLargo® AOS Filter extends the life of filtration systems, reduces corrosion, and conserves chemistry. BioLargo’s Canadian subsidiary, BioLargo Water, Inc. initiated a prototype development project for its AOS Filter technology.

The BioLargo® AOS Filter facilitates ongoing and scalable treatment with maximum efficiency employing GRAS components to convert contaminates to H2O and CO2.  It destroys hard to get contaminates and disinfects quickly and completely. The BioLargo® AOS Filter is complementary with many filter systems.

BioLargo’s subsidiary, Odor-No-More, Inc., features award-winning products serving the pet, equine, military supply, and consumer markets. This includes the Nature's Best Solution® and Deodorall® brands.

Also, BioLargo’s subsidiary, Clyra Medical Technologies, Inc., concentrates on advanced wound care management. In addition, BioLargo owns a 50 percent interest in the Isan System. This system was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project, now under license to Clarion Water, Inc.

CupriDyne® Clean Industrial Odor Eliminator is made by Odor-No-More, BioLargo’s subsidiary. Odor-No-More has signed what are known as national purchasing or national supply agreements with three leading U.S. waste handling companies.

Recently, BioLargo announced that its subsidiary Clyra Medical Technologies submitted to the Food & Drug Administration (FDA) an application for premarket notification under Section 510(k) of the Food, Drug, and Cosmetic Act for a wound care product. By statute, Clyra must wait 90 days before going to market while the FDA evaluates the submission and determines whether to grant it clearance.

Regarding CupriDyne Clean Industrial Odor Control, this year, product sales have increased each quarter. This is from roughly $50,000 in Q1, to almost $100,000 in Q2, and $170,000 in this last quarter. This represents roughly a 100 percent increase from Q1 to Q2, and a 70 percent increase in sales from Q2 to Q3. The Company is engaged in numerous odor-control trials in the wastewater treatment industry. It is enjoying early success with municipal clients.

This past September, BioLargo started a full service in-house environmental engineering firm. It created a wholly-owned subsidiary called BioLargo Engineering, Science & Technologies, LLC.

BioLargo, Inc. (BLGO), closed Tuesday's trading session at $0.405, down 2.41%, on 27,655 volume with 11 trades. The average volume for the last 60 days is 80,806 and the stock's 52-week low/high is $0.38/$0.90.

Aeolus Pharmaceuticals, Inc. (AOLS)

Buzz Stocks, BullRally, CoolPennyStocks, HotOTC, Stock Rich, Penny Invest, Sling-Shot-Stocks, StockEgg, Marketbeat, Stock News Now, TaglichBrothers, Ceocast News, SmallCapVoice, and Top Secret Stocks reported earlier on Aeolus Pharmaceuticals, Inc. (AOLS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aeolus Pharmaceuticals, Inc. is a biotechnology company headquartered in Mission Viejo, California. It is developing compounds to protect against fibrosis, inflammation, nerve damage, as well as infection. The Company is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds, which protect healthy tissue from the damaging effects of radiation. Aeolus’ initial and lead compound is AEOL 10150. AEOL 10150 is a broad-spectrum catalytic antioxidant. In addition, the Company has its oral Parkinson's disease drug AEOL 11114. Aeolus Pharmaceuticals’ shares trade on the OTC Markets’ OTCQB.

The Company’s strategy is to take advantage of the considerable investment in toxicology, manufacturing, and preclinical and clinical studies made by U.S. Government agencies in AEOL 10150 to efficiently develop the compound for use in idiopathic pulmonary fibrosis and oncology. AEOL 10150 is undergoing development, with funding by the U.S. Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, and a treatment for pulmonary fibrosis.

Aeolus Pharmaceuticals is developing AEOL 10150 as a treatment for the pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and delayed effects of acute radiation exposure (DEARE) under a five-year contract with BARDA worth up to $118.4MM. BARDA is a division of the U.S. Department of Health and Human Services.

Furthermore, AEOL 10150 is undergoing study by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal tract and by NIH CounterACT as a countermeasure against chlorine gas and sulfur mustard gas exposure.

Aeolus Pharmaceuticals announced in February of this year the start of a Phase 1 study with its lead compound AEOL 10150. This Phase 1 study is an open-label, single center, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of an escalating single dose of AEOL 10150 administered by subcutaneous injection in healthy subjects.

In June, Aeolus Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AEOL 10150 for the prevention of fatal respiratory failure among patients at risk for radiation pneumonitis following a radiological/nuclear incident sufficient to cause the Acute Radiation Syndrome (Lung-ARS).

In September, Aeolus announced presentation of pharmacometric-based analysis confirming the optimal dosing schedule for AEOL 10150 in the treatment of the pulmonary effects of Acute Radiation Syndrome (Lung ARS). The analysis was performed by Jogarao Gobburu, PhD, Vijay Ivaturi, PhD, and Hechuan Wang, MS with the Center for Translational Medicine at the University of Maryland School of Pharmacy and funded by Aeolus Pharmaceuticals’ Lung ARS development contract with the Biomedical Advanced Research and Development Authority (BARDA).

The analysis confirmed the statistical significance of the improvement in survival and underlying pathophysiology observed after treatment with AEOL 10150 in NHP efficacy studies conducted by and earlier reported by Thomas MacVittie, PhD at the University of Maryland School of Medicine (UMSOM).

Dr. Gobburu's analysis of data from NHP and mouse efficacy studies, performed under the BARDA contract, concluded that administration of AEOL 10150 for 60 days commencing 24 hours after exposure to lethal radiation provided the best survival benefit. Dr. Gobburu's analysis also concluded that this level of efficacy demonstrated in an "adequate and well designed" study would likely produce a dose modification factor supporting approval under the Animal Rule.

Aeolus Pharmaceuticals, Inc. (AOLS), closed Tuesday's trading session at $0.10, even for the day, on 18,925 volume with 10 trades. The average volume for the last 60 days is 18,264 and the stock's 52-week low/high is $0.0525/$0.25.

BeWhere Holdings, Inc. (BEWFF)

OTC Markets, Barchart, Marketwired, and Stockhouse reported on BeWhere Holdings, Inc. (BEWFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BeWhere Holdings, Inc. is an Industrial Internet of Things (IoT) solutions company listed on the OTC Markets Group’s OTCQB. The Company designs and sells hardware with sensors and software applications for environmental sensing and to track real-time information on assets. The founders and management team of BeWhere Holdings were co-founders or early-stage employees of telematics businesses. BeWhere Holdings has its corporate office in Toronto, Ontario.

The Company’s solutions enable end-users a level of operational visibility, which is more easily accessible and considerably easier to implement than in the past. BeWhere Holdings develops mobile applications, middle-ware and cloud based solutions that stand-alone or that can be promptly integrated with existing software.

BeWhere Holdings has go-to-market partners and Value Added Resellers in each of its industry verticals. Patents have been filed around the Company’s core technology.

BeWhere Beacons are equipped with multiple sensors measuring battery life, temperature, proximity, light, impact, and more. This permits its solution to target numerous industries and markets across many use cases. The Company’s focused industry verticals represent tens of millions of beacon sale opportunities.

BeWhere has developed a ruggedized beacon. It utilizes Low-Energy Bluetooth® technology that is easy to set up. The Company’s technology has the same spectrum of applications that RFID tags offer.

Last month, BeWhere Holdings announced the implementation and rollout of an advanced Mobile Safety Solution providing enhanced security for Brink's Canada operations. BeWhere has previously partnered with Brink's to provide compliance, safety, and security solutions that enable assets to be safely monitored.

The Mobile Safety Solution increases personnel security, providing enhanced visibility and communication between the guards and Brink’s state-of-the-art network communications center. Brink's worldwide network has operations in 41 countries and serves customers in over 100 countries.

Earlier this month, Bell announced it has partnered with BeWhere Technologies and Huawei to implement an automated Internet of Things (IoT) solution for the Henry of Pelham vineyard in the Province of Ontario to help improve planning and sustainability programs. Through using wireless environmental sensors connected to Bell's LTE-M wireless network, the winery will be able to remotely monitor temperature and water levels, prevent vine disease, and ultimately improve the health of its plants. This will decrease operating costs and provide for years of maintenance-free data gathering.

LTE-M improves the operating efficiency of IoT devices. It does so through enabling very low power consumption and better coverage in underground and other hard-to-reach locations. In partnership with Huawei, Bell has successfully demonstrated these benefits in its Mississauga, Ontario wireless innovation lab and in network field trials.

Bell is Canada's largest communications company. Huawei is a foremost worldwide information and communications technology (ICT) solutions provider.

BeWhere Holdings, Inc. (BEWFF), closed Tuesday's trading session at $0.401, down 0.74%, on 4,500 volume with 1 trade. The average volume for the last 60 days is 5,593 and the stock's 52-week low/high is $0.177/$0.4451.

Protea Biosciences Group, Inc. (PRGB)

INO Market Report and SmallCapVoice reported earlier on Protea Biosciences Group, Inc. (PRGB), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Protea Biosciences Group, Inc. is a molecular information company listed on the OTC Markets Group’s OTCQB. The Company provides proprietary bio-analytical technology to the pharmaceutical and life science industries. It does so through applying its proprietary technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules, which are the by-products of all living cells and life forms. Protea is the leader in mass spectrometry imaging services (MSI). Protea Biosciences has its corporate office in Morgantown, West Virginia.

Protea’s proprietary technology enables direct molecular imaging (the ability to identify and display biomolecules in tissue and cells, without sample pre-treatment). The Company delivers strong molecular information to medical and life science researchers worldwide. Protea focuses on meeting the needs of the pharmaceutical, biotechnology, agriculture, chemical, and other industries with inventive technologies, software, and services.

Regarding MSI Services, the Company’s research laboratory brings access to the most advanced and innovative MSI technologies and workflows. Protea maintains its own laboratory facility. At this facility, it performs services using (Laser Ablation Electrospray Ionization) LAESI® and complementary technologies for a broad array of customers to support preclinical pharmaceutical research and development (R&D), biomarker discovery, and other applications.

The LAESI DP-1000 is an integrated system. It combines LAESI and ProteaPlot™. The LAESI system is a next generation molecular imaging platform. It directly analyzes biological samples without the requirement to apply chemicals or introduce tags or tracers. It enables 2-dimensional and 3-dimensional imaging, displaying the distribution of molecules in the samples.

The Company’s proprietary technology, LAESI®, is used with mass spectrometry to detect the presence of up to, and over, 1,000 distinct molecules from a single analysis of samples that can include tissues, cells, fluids, agricultural specimens, and other sample kinds. Utilizing proprietary software, the location of each distinct molecule in a respective sample can be displayed. This enables direct molecular imaging. Protea Biosciences also collaborates with researchers to apply its technologies and expertise to generate new discoveries and intellectual property (IP).

This past August, Protea Biosciences announced that it entered into a Collaboration Research Agreement with the Vaccine and Immunotherapy Center (VIC), Division of the Massachusetts General Hospital (MGH) and Harvard Medical School. The aim is to co-develop a new diagnostic methodology that will provide cancer cell molecular profiles, including the distribution of drugs within cancer cells and molecular response indicators, to improve patient treatment and outcomes.

Furthermore, in August, Protea announced it expanded its clinical research study for its new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now exceeded 250 patient samples.

Last month, Protea Biosciences announced that it plans to develop clinical screening assays in different areas of oncology. The assays shall undergo development on Bruker's rapifleX™ MALDI Tissuetyper™ using Protea Biosciences’ proprietary histology guided mass spectrometry workflows and expertise. Protea has already performed initial clinical research studies to utilize mass spectrometry to more accurately differentiate malignant and benign melanocytic lesions through monitoring protein levels in standard biopsy samples.

Protea Biosciences Group, Inc. (PRGB), closed Tuesday's trading session at $0.09, down 10.00%, on 2,000 volume with 3 trades. The average volume for the last 60 days is 961 and the stock's 52-week low/high is $0.10/$7.75.

CurAegis Technologies, Inc. (CRGS)

OTC Markets and InvestorsHub reported on CurAegis Technologies, Inc. (CRGS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, CurAegis Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The Company consists of two independent divisions - its CURA Division and its Aegis Division. CurAegis is presently focusing on commercialization strategies in varied technologies. These include the CURA system, which includes the myCadian™ watch that measures degradation of alertness and sleep attributes; the Z-Coach e-learning education and training tool, and the Aegis hydraulic pump. CurAegis Technologies is headquartered in Rochester, New York.

The CURA System consists of hardware and software that measures manifold metrics to establish that a person's ability to perform a task or job appears to be degrading. The CURA division is developing a proprietary technology and family of products designed to measure the decrease in a person’s alertness and to train persons on how to improve alertness levels.

The CURA™ system and the myCadian™ watch enable the user and third parties to anticipate and prevent undesired or disastrous situations caused by the degradation of alertness. CurAegis Technologies completed its validation studies of the CURA System at the University of Colorado at Boulder and the University of Rochester Medical Center. The Company earlier said that it can now state that it can predict a person’s fatigue level, at close to laboratory accuracy, in real-time.

The Z-Coach e-learning tool was acquired by CurAegis Technologies in September 2015. The first of six Z-Coach e-learning modules, Z-Coach Aviation, was designed for aviation professionals. If the CURA (Circadian User Risk Assessment) software detects an issue, Z-Coach creates a back-end solution required to induce change and improve behavior. The program is broken down into two parts: Z-Coach Education and Z-Coach Intervention.

Moreover, the Company’s Aegis hydraulic pump (Aegis Division) is a unique hydraulic design. Its objective is to deliver better efficiencies in a package that is smaller and lighter than contemporary technologies.

Concerning the Aegis Division’s Aegis Pump and Motor, it has eliminated the rotating piston group (the cylinders are stationary). This makes the pump very strong and easy to manufacture. The Company’s patented valving has been integrated to increase efficiencies at peak and off peak operation.

The Company’s plan is to license its technology to major manufacturers. It may consider an exclusive licensing agreement for a period of time if it believes that it is the best way to reach the original equipment manufacturer (OEM) and after-market customers.

Concerning the CURA System, it now works with iOS and Android phones. The Company has aligned the communications between its watch, the smart phone and its cloud.

The CURA System will make an individual aware of the importance of sleep in their daily life. It will show one how to easily change their behavior to make their life safer, healthier, and longer. In addition, it gives a person accurate and relevant real-time information about their current and long-term sleep and fatigue health.

CurAegis Technologies, Inc. (CRGS), closed Tuesday's trading session at $0.33, up 10.00%, on 82,081 volume with 10 trades. The average volume for the last 60 days is 16,717 and the stock's 52-week low/high is $0.27/$1.91.

Rego Payment Architectures, Inc. (RPMT)

Investing, InvestorsHub, and MarketWatch reported on Rego Payment Architectures, Inc. (RPMT), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Rego Payment Architectures, Inc. formerly operated under the name Virtual Piggy, Inc. On March 16, 2017, the Company, creators of the only COPPA compliant technology targeted at providing payment capability for the under 18 market, announced its name change to reflect the progression of the Company into broader payment-related markets. Rego Payment Architectures lists on the OTC Markets Group’s OTCQB.

REGO Payment Architectures, Inc. became an umbrella under which the Intellectual Property (IP) developed becomes available to many different industries beyond the under 18 market. Rego Payment Architectures is headquartered in Palm Beach, Florida.

The Company’s core technology base is established on validated artificial intelligence (AI) techniques. It has extensive capability to adapt to a wide assortment of payment markets and users.

The core technology comprises ReTRO (Real Time Regulatory Oversight), established on advanced AI techniques, a system of reasoning engines, and a Contract Model (CM), which permits the creation of specific boundary conditions for its use.

Rego also has its NOMad (Networks of Meaning ad-vantage). This is an advanced data mining application that monitors people and the things they interact with. Furthermore, the Company has its RSM (REGO Payment Architectures, Secure Financial Messaging) - the payment control system.

REGO Payment Architectures signed a definitive agreement with Be Informed BV, effective July 2017, for the Company’s commercial launch of its unique digital mobile payment system. The terms and conditions allow Rego's COPPA compliant OINK payment platform unlimited use of its developed technology to be available to children and their families for direct mobile payments.

In addition, Rego Payment Architectures and Be Informed entered into three new MOU’s in expectation of the many and diverse expanding markets where this mobile payment technology will be advantageous. The MOU's allow Rego to enter into production agreements under like terms and conditions to its OINK payment platform. The agreements cover the expected welfare benefits, the unbanked and closed loop platforms.

REGO Payment Architectures has its Beta version of the OINK Payment System for Children. OINK (Online Instant Networking Keypad) is a technology that speeds up payments and makes making payments simple and streamlined.

Fundamentally, Rego Payment Architectures is redirecting its efforts to instant Peer to Peer (P2P) transfers employing mobile phones and online systems. The Company’s new business model is an instant revenue producing membership system. It provides Rego Payment Architectures with greater flexibility in fund management. It also provides extra layers of security to protect members’ privacy and their transactions.

Rego Payment Architectures, Inc. (RPMT), closed Tuesday's trading session at $0.23, down 7.63%, on 51,159 volume with 11 trades. The average volume for the last 60 days is 25,942 and the stock's 52-week low/high is $0.10/$0.489.

Eco Tek 360, Inc. (ECTX)

MarketWatch, InvestorsHub, and TradingView reported on Eco Tek 360, Inc. (ECTX), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Eco Tek 360, Inc. provides contemporary, sustainably sourced casual clothing. The Company’s patented green technology allows it to provide sustainable uniforms. Eco Tek 360 centers on providing branded fabrics, apparel, and uniforms to the corporate, hotel, hospital, and military markets.

The Company previously went by the name Global Fashion Technologies, Inc. It changed its name to Eco Tek 360, Inc. in January of 2017. Established in 2004, Eco Tek 360 has its corporate headquarters in Somerville, New Jersey. The Company lists on the OTCQB.

Eco Tek 360’s state-of-the-art green technology allows it to collect and rejuvenate a customer’s used uniforms into new uniforms. Eco Tek 360 rejuvenates old uniforms and recovers the fiber to spin yarn, make fabric, and cut and sew new uniforms in its United States based facility.

Eco Tek 360’s program for its customers is a four-step process. This process includes Recovery; Rejuvenation; Creation; and Shipping.

Regarding Recovery, a customer collects/recovers their old uniforms and sends them to the Company. Through controlling their used uniforms, a customer improves their security. They receive a credit that is good toward their subsequent uniform purchase.

Regarding Rejuvenation, Eco Tek 360’s patented process purifies old fiber into new, sustainably-sourced uniforms. This rejuvenated fiber is soft and strong. Furthermore, it saves 6,200 liters per cotton shirt.

Concerning Creation, the Company cuts and sews new uniforms from the rejuvenated fiber. Pertaining to Shipping, a customer’s new uniforms are ready for purchasing in Eco Tek 360’s secure online store. They are shipped directly to the customer.

Eco Tek 360’s quality process is integrated from the collection of customers’ old uniforms through delivery to them from its New Jersey warehouse. The Company’s in-house capabilities ensure versatility, first-rate design, and responsiveness to support small batch construction for specialty products, unique sizing, and personalization with quick turn times.

Eco Tek 360, Inc. (ECTX), closed Tuesday's trading session at $0.17, up 11.48%, on 9,000 volume with 2 trades. The average volume for the last 60 days is 6,121 and the stock's 52-week low/high is $0.05/$0.56.


The QualityStocks
Company Corner


Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.404, off by 8.18%, on 255,221 volume with 92 trades. The stock’s average daily volume over the past 60 days is 31,102 and its 52-week low/high is $0.171/$0.48.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is “One to Watch”

Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain

Veritas Pharma Enters Binding Letter of Intent to Secure ACMPR License and Cannabis Growing Facility


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.939, up 3.99%, on 504,810 volume with 364 trades. The stock’s average daily volume over the past 60 days is 306,014 and its 52-week low/high is $0.6171/$1.25.

NetworkNewsWire Coverage: For 17 years Canada has provided legal access to medical cannabis to its citizens, and now the country is expected to legalize recreational marijuana by July 2018. With sales of Canadian medical cannabis projected to exceed $8 billion by 2024 (http://nnw.fm/bEi4r) and the recreational market estimated to be worth over $18 billion annually (http://nnw.fm/x49Ay), investment capital has been pouring into Canada’s licensed producers (LPs). Though the demand for cannabis is projected to exceed 600,000 kilograms a year (about 1.3 million pounds), Canada’s LPs currently only cultivate about 20,000 pounds of dried marijuana annually. This immense impending imbalance is a magnet for serious capital investment. It also presents enormous domestic opportunities for one of Canada’s premier producers, ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) (ABCCF Profile), which produces only organically grown, pesticide-free, standardized product and produces among the highest yields within the Canadian sector.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

Outsized Demand in Canada’s Cannabis Market Triggers Upswing in Smart Money Flowing North

Coming Cannabis Recreational Demand in Canada Triggers Massive Investment

ABcann Global Strengthens Board and Executive Team

First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.596, up 3.47%, on 58,015 volume with 33 trades. The stock’s average daily volume over the past 60 days is 64,857, and its 52-week low/high is $0.3148/$0.67.

First Cobalt Corp. (FTSSF) is pleased to announce several high grade cobalt outcrop and muckpile samples from the Caswell mine in the Cobalt Camp. A prospecting program identified the high grade mineralization at surface in the Cobalt Central area of the Cobalt Camp in Ontario, Canada, including 9.44% cobalt, 1.27% copper and 2.92% nickel. Highlights include grab samples at the former Caswell mine confirm high grade cobalt at surface and at shallow depths, including cobalt grades of 9.4%, 4.8%, 6.1% and 1.1%. These results along with pending assays from other historic mines owned by First Cobalt have prompted a dedicated exploration program to quickly assess near-surface high grade cobalt mineralization through shallow drilling, bore-hole geophysical surveys near historic workings and ground geophysics over larger areas.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

First Cobalt Reports 9.4% Cobalt Sample from Caswell Mine Prospecting Program

Cobalt One Shareholders Overwhelmingly Approve Merger with First Cobalt

First Cobalt Begins Assessment of Economic Potential of Historic Muckpile Material

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0222, up 5.71%, on 14,658,355 volume with 591 trades. The stock’s average daily volume over the past 60 days is 3,296,045, and its 52-week low/high is $0.009/$0.04.

Global Payout, Inc. (GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. established a significant and successful presence during its attendance last week at the 2017 Marijuana Business Convention ("MJBizCon") in Las Vegas, NV where the Company was represented by COO, Vanessa Luna and PotSaver Founder, Aaron Adler.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

MoneyTrac Technology, Inc. Attends 2017 MJBizCon and Establishes Key Industry Connections for the Growth of the PotSaver Brand and Progress with the Development of Its Banking Solution

Global Payout’s MoneyTrac Technology, Inc. and Strategic Partner Pegasus Fintech, Inc. Move Closer to Launch of their Regulatory Complaint Token Offering for the Cannabis Industry

Global Payout’s Subsidiary, MoneyTrac Technology Inc. Explores Partnerships with Compliance Firms in the Cannabis Banking Sector

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.0595, up 2.59%, on 3,368,935 volume with 224 trades. The stock’s average daily volume over the past 60 days is 3,024,133, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding Inc. (POTN) CEO Dr. Richard Goulding will discuss the company’s recent success and promising future on “THE SHOW.” Interviewed by Mick Bazsuly, Dr. Goulding will be highlighting recent developments and the corporate vision as the Company prepares to enter 2018. THE SHOW the R.P. Summit Business Hour can be heard Tuesday at 10 A.M. on 95.3 FM and 1470 AM South Florida as well as www.wwnnradio.com and viewed live on www.amp2.tv worldwide. The show now in its 17th year on Beasley Broadcasting features up and coming companies, new products and hot ideas from businesses worldwide.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

National Radio and Web Broadcast to Feature PotNetwork on R.P. Summit Business Hour on Tuesday, November 21, 2017

PotNetwork Holding, Inc. Reports Revenues of $1,694,788 for October, Surpassing September Results by over Half a Million Dollars

PotNetwork Subsidiary Diamond CBD to Exhibit at the 6th Annual Las Vegas MJBizCon Event

Bollente Companies, Inc. (BOLC)

The QualityStocks Daily Newsletter would like to spotlight Bollente Companies, Inc. (BOLC). Today, Bollente Companies, Inc. closed trading at $0.80, even for the day, on 2,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 418 and its 52-week low/high is $0.20/$1.21.

Bollente Companies, Inc. (BOLC) is in the early stages of developing a diverse portfolio of companies, targeting disruptive technologies that positively impact the environment and emerging economies. Their current focus is on high-efficiency electric tankless water heaters, manufactured and sold under "trutankless", a division of Bollente, including a line of economy tankless water heaters sold under the Vero name. Units are available for both residential and commercial application.

The primary Bollente advantage is their use of advanced technology, superior to previous tankless systems, together with a growing U.S. and global market. Traditional water heaters are one of the costliest appliances to operate. The two primary energy sources used in U.S. homes are electric and natural gas, with less than half of U.S. homes having natural gas available. In addition, there are no significant electric whole home tankless manufacturers.

The U.S. Department of Energy now requires tanks of 55 gallons or more to have efficiency levels requiring expensive heat pumps to achieve. Bollente's trutankless electric tankless water heater employs specialized sensors for constant water temperature, solid state electronics, and proprietary software, resulting in one of the most efficient heat exchangers ever produced. The technology includes smart grid and home automation capabilities, remote control and monitoring, and even smartphone alerts. It also allows adjustable custom power management settings, so that users can further enhance energy usage and performance. It is now estimated that tankless heaters used in every home would save over $8 billion annually in the U.S. alone.

By maintaining 99 percent efficiency, Bollente's trutankless heaters use less energy than tank heaters, while providing the convenience of always-hot water. The system only uses power when there is demand, producing water to exact temperature, within one degree, even with sudden changes to input. Wireless apps allow for remote settings, notifications, and monitoring, and models are compatible with existing home automation and energy management systems. The technology also reduces size, for easy location, and the system's self-flushing design provides up to 20+ years of maintenance free operation, significantly reducing upkeep and replacement costs. This becomes an additional environmental benefit since roughly 8 million used water heaters are dumped in landfills every year.

Bollente has also announced the formation of Bollente International, Inc., a wholly-owned subsidiary, for the international production and sale of trutankless systems. Taking advantage of growing interest in their technology, Bollente International is working with an international manufacturing firm for the production and distribution of trutankless systems throughout Europe, Asia, Australia and New Zealand, with the first step being the testing and certification necessary to meet the various international standards.

Bollente has made electric tankless water heating compelling to a major consumer market, both in and outside the U.S., offering economic as well as operational efficiency and convenience, attractive to builders as well as to end consumers. Disclaimer

Bollente Companies, Inc. Blog

Bollente Companies, Inc. News:

Bollente Companies' trutankless® Partners with Ferguson for Nationwide Distribution Program

Bollente Companies Increases Production and Distribution Capabilities for trutankless® with Global Manufacturing Partnership

Bollente Companies Increases Presence in Trending Segment of Commercial Construction with Its Smart trutankless Product Line

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG). Today, Medical Cannabis Payment Solutions closed trading at $0.03625, off by 2.68%, on 283,382 volume with 36 trades. The stock’s average daily volume over the past 60 days is 333,280, and its 52-week low/high is $0.0161/$0.20.

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company's state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company's unique "StateSourced" proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven't been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin's cryptocurrency ($Weed) with Medical Cannabis Payment Solutions' StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

"We've completed our transition from development stage to revenue stage," says Roberts. "We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases."

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry. Disclaimer

Medical Cannabis Payment Solutions Company Blog

Medical Cannabis Payment Solutions News:

Medical Cannabis Payment Solutions (REFG) is “One to Watch”

Medical Cannabis Payment Solutions (REFG) to Purchase Industry Leading Cryptocurrency, Launch Joint Venture Aimed at Alternative Payment Solution for the Cannabis Industry

Medical Cannabis Payment Solutions Announces First Payment Processing Customer


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(EKSO) +41.44%


(CLSN) +33.64%


(PQEFF) +32.32%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251